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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
astaxanthin and protection of the skin from UV-induced damage (ID 1687, 
1979), defence against Helicobacter pylori (ID 1686), contribution to normal 
spermatogenesis (ID 1688), contribution to normal muscle function 
(ID 1685), and “immune system” (ID 1689, 1919, 1980) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to astaxanthin and protection of the skin from UV-induced damage, defence against 
Helicobacter pylori, contribution to normal spermatogenesis, contribution to normal muscle function, 
and “immune system”. The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is astaxanthin. The Panel considers that 
astaxanthin is sufficiently characterised. 
Protection of the skin from UV-induced damage 
The claimed effects are “skin health” and “protects skin from UV damage and sun exposure”. The 
target population is assumed to be the general population. The Panel considers that protection of the 
skin from UV-induced damage is a beneficial physiological effect. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-2421, EFSA-Q-2008-2422, EFSA-Q-2008-2423, 
EFSA-Q-2008-2424, EFSA-Q-2008-2425, EFSA-Q-2008-2652, EFSA-Q-2008-2712, EFSA-Q-2008-2713, adopted on 
25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Gut/Immune: Jean-Louis Bresson, Maria Carmen Collado, Miguel Gueimonde, Daisy Jonkers, Martinus Løvik, Bevan 
Moseley, Maria Saarela, Seppo Salminen, Yolanda Sanz, Stephan Strobel, Daniel Tomé and Hendrik van Loveren. 
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No human studies have been provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of astaxanthin and protection of the skin from UV-induced 
damage. 
Defence against Helicobacter pylori 
The claimed effect is “gut health: influence on Helicobacter pylori infection”. The target population 
is assumed to be the general population. The Panel considers that defence against Helicobacter pylori 
is a beneficial physiological effect. 
No human studies have been provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of astaxanthin and defence against Helicobacter pylori. 
Contribution to normal spermatogenesis 
The claimed effect is “sperms motility”. The target population is assumed to be the general male 
population. The Panel considers that contribution to normal spermatogenesis is a beneficial 
physiological effect. 
In weighing the evidence, the Panel took into account that the one human intervention study provided 
did not show an effect of astaxanthin, compared to placebo, on various measures of sperm quality in 
males. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of astaxanthin and contribution to normal spermatogenesis. 
Contribution to normal muscle function 
The claimed effect is “muscle function”. The target population is assumed to be the general 
population. The Panel notes that from the information provided the aspect of muscle function which is 
the subject of the health claim is unclear. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
“Immune system” 
The claimed effects are “immune system” and “supports healthy immune system”. The target 
population is assumed to be the general population. 
The references provided addressed several outcomes, and it was not possible to establish which effect 
is the target for the claim. Given the multiple roles of the immune system, the specific aspect of 
immune function that is the subject of the claim needs to be specified, but has not been indicated in 
the information provided.  
The Panel considers that the claimed effects are general and non-specific, and do not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is astaxanthin. 
Astaxanthin is a red (non-provitamin A) oxygenated carotenoid found in phytoplankton, and is 
responsible for the colour of certain fish (e.g. salmon) and shellfish (e.g. crab).  
Astaxanthin occurs naturally in foods and also in synthetic forms as free astaxanthin or in the form of 
esters. Astaxanthin is absorbed into the bloodstream as the free form, and bioavailability can be 
enhanced in lipid matrices. Astaxanthin is measurable in foods by established methods. 
The Panel considers that the food constituent, astaxanthin, which is the subject of the health claims, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
2.1. Protection of the skin from UV-induced damage (ID 1687, 1979) 
The claimed effects are “skin health” and “protects skin from UV damage and sun exposure”. The 
Panel assumes that the target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
protection of the skin from UV-induced damage (sunburn). 
The Panel considers that protection of the skin from UV-induced damage is a beneficial physiological 
effect.  
2.2. Defence against Helicobacter pylori (ID 1686) 
The claimed effect is “gut health: influence on Helicobacter pylori infection”. The Panel assumes that 
the target population is the general population. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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Influence on Helicobacter pylori infection could be interpreted as defence against Helicobacter 
pylori. 
The Panel considers that defence against Helicobacter pylori is a beneficial physiological effect. 
2.3. Contribution to normal spermatogenesis (ID 1688) 
The claimed effect is “sperms motility”. The Panel assumes that the target population is the general 
male population. 
In the context of the proposed wordings and references provided, the Panel assumes that the claimed 
effect refers to normal spermatogenesis. 
The Panel considers that contribution to normal spermatogenesis is a beneficial physiological effect. 
2.4. Contribution to normal muscle function (ID 1685) 
The claimed effect is “muscle function”. The Panel assumes that the target population is the general 
population. 
The references provided in relation to this claim included human intervention studies on the effects of 
astaxanthin on endurance capacity, endurance performance, muscle strength, and muscle fatigue 
during exercise, and animal studies on the effects of astaxanthin on exercise-induced skeletal and 
cardiac muscle damage, and skeletal muscle fatigue. The Panel notes that from the information 
provided the aspect of muscle function which is the subject of the health claim is unclear.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
2.5. “Immune system” (ID 1689, 1919, 1980) 
The claimed effects are “immune system” and “supports healthy immune system”. The Panel assumes 
that the target population is the general population. 
The claimed effects are not sufficiently defined, and no further details were given in the proposed 
wordings or clarifications provided by Member States. The Panel notes that the references provided 
addressed several outcomes, and that it was not possible to establish which effect is the target for the 
claim. Given the multiple roles of the immune system, the specific aspect of immune function that is 
the subject of the claim needs to be specified, but has not been indicated in the information provided.  
The Panel considers that the claimed effects are general and non-specific, and do not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
3. Scientific substantiation of the claimed effect 
3.1. Protection of the skin from UV-induced damage (ID 1687, 1979) 
The references provided included narrative reviews on the effects of carotenoids in general and/or of 
astaxanthin on different health outcomes, including protection of the skin from UV-induced damage, 
which did not provide any original data which could be used for the scientific substantiation of the 
claim, or human intervention studies on the effects of carotenoids other than astaxanthin. The Panel 
Astaxanthin related health claims 
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considers that no conclusions can be drawn from these references for the scientific substantiation of 
the claim. 
One open label, uncontrolled human intervention study which investigated the effects of astaxanthin 
consumption (4 mg/day) for two weeks on the minimal erythemal dose in 21 healthy male and female 
subjects (Cheun et al., year not given) was provided. The Panel considers that no conclusions can be 
drawn from this uncontrolled study for the scientific substantiation of the claim. 
A number of animal and in vitro studies reported on the effects of astaxanthin on UV-induced cellular 
damage to the skin or cultured cells (e.g. cyst cells and fibroblasts). The Panel considers that evidence 
provided in animal and in vitro studies is not sufficient to predict the occurrence of an effect of 
astaxanthin consumption on protection of the skin from UV-induced damage in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of astaxanthin and protection of the skin from UV-induced damage. 
3.2. Defence against Helicobacter pylori (ID 1686) 
Among the references provided for the scientific substantiation of the claim were animal and human 
intervention studies which addressed health outcomes (i.e. markers of oxidative stress in patients with 
reflux oesophagitis before and after anti-reflux surgery; experimental gastritis, oesophagitis, gastric 
ulcers in mice, rat and guinea pig models) unrelated to the claimed effect, and one human intervention 
study which was not accessible to the Panel after every reasonable effort had been made to retrieve it. 
Kupcinskas et al. (2008), in a placebo-controlled, randomised, double-blind study, evaluated the 
effect of astaxanthin (16 or 40 mg/day) given for four weeks on gastrointestinal discomfort assessed 
with the Gastrointestinal Symptom Rating Scale questionnaire and the SF-36 quality of life 
questionnaire. The Panel notes that the effect of astaxanthin on Helicobacter pylori infection was not 
addressed in this study. 
The animal studies provided evaluated the effect of astaxanthin on the treatment of Helicobacter 
pylori infection. The Panel considers that evidence provided in animal studies is not sufficient to 
predict the occurrence of an effect of astaxanthin consumption on defence against Helicobacter pylori 
infection in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of astaxanthin and defence against Helicobacter pylori. 
3.3. Contribution to normal spermatogenesis (ID 1688) 
Two references were submitted for the scientific substantiation of the claim. 
In a randomised, double-blind, placebo-controlled human intervention study, 20 men with infertility 
for ≥12 months received conventional treatment according to the guidelines of the World Health 
Organization (WHO), and either astaxanthin (16 mg/day, n=11) or placebo (n=9) for three months. 
Ten additional patients receiving placebo who had participated in another parallel, placebo-controlled 
trial were included in the analysis. No statistically significant differences were observed between the 
astaxanthin and placebo groups with respect to changes in any of the variables used to assess sperm 
quality (e.g. sperm concentration, linear velocity, grade (a) motility, sperm morphology, ejaculate 
volume, zona-free hamster oocytes test, spermatozoa firmly attached/oocytes, and decondensed sperm 
heads/oocytes) during the study. The Panel notes that this study did not show an effect of astaxanthin 
consumption on sperm quality. 
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An animal study on the effects of astaxanthin consumption on semen quality and fertility in stallions 
during the breeding period (Heczko, 2004) was also provided. The Panel considers that evidence 
provided in animal studies is not sufficient to predict the occurrence of an effect of astaxanthin 
consumption on contribution to normal spermatogenesis in humans. 
In weighing the evidence, the Panel took into account that the one human intervention study provided 
did not show an effect of astaxanthin, compared to placebo, on various measures of sperm quality in 
males. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of astaxanthin and contribution to normal spermatogenesis. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, astaxanthin, which is the subject of the health claim, is sufficiently 
characterised. 
Protection of the skin from UV-induced damage (ID 1687, 1979) 
 The claimed effects are “skin health” and “protects skin from UV damage and sun exposure”. 
The target population is assumed to be the general population. Protection of the skin from 
UV-induced damage is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
astaxanthin and protection of the skin from UV-induced damage. 
Defence against Helicobacter pylori (ID 1686) 
 The claimed effect is “gut health: influence on Helicobacter pylori infection”. The target 
population is assumed to be the general population. Defence against Helicobacter pylori is a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
astaxanthin and defence against Helicobacter pylori. 
Contribution to normal spermatogenesis (ID 1688) 
 The claimed effect is “sperms motility”. The target population is assumed to be the general 
male population. Contribution to normal spermatogenesis is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
astaxanthin and contribution to normal spermatogenesis. 
Contribution to normal muscle function (ID 1685) 
 The claimed effect is “muscle function”. The target population is assumed to be the general 
population. From the information provided, the aspect of muscle function which is the subject 
of the health claim is unclear. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
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“Immune system” (ID 1689, 1919, 1980) 
 The claimed effects are “immune system” and “supports healthy immune system”. The target 
population is assumed to be the general population. The references provided addressed 
several outcomes, and it was not possible to establish which effect is the target for the claim.  
 The claimed effects are general and non-specific, and do not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2421, 
EFSA-Q-2008-2422, EFSA-Q-2008-2423, EFSA-Q-2008-2424, EFSA-Q-2008-2425, EFSA-Q-2008-
2652, EFSA-Q-2008-2712, EFSA-Q-2008-2713). The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES 
Cheun O, Shanahan R and Wood C, year not given. Clinical Evaluation of the Potential of an 
Antioxidant Supplement to Alter Photobiological Responsiveness in Humans using 
BioAstin®. Protocol: CLCO-001, Final Report. 
Heczko KH, 2004. Effects on semen quality and fertility by feeding carotinoid astaxanthin to stallions 
during the breeding period. Doctoral thesis, University of Veterinary Medicine, Hanover, 128 
pp. 
Kupcinskas L, Lafolie P, Lignell A, Kiudelis G, Jonaitis L, Adamonis K, Andersen LP and Wadstrom 
T, 2008. Efficacy of the natural antioxidant astaxanthin in the treatment of functional 
dyspepsia in patients with or without Helicobacter pylori infection: A prospective, 
randomized, double blind, and placebo-controlled study. Phytomedicine, 15, 391-399. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to astaxanthin, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
 
ID Food or Food constituent Health Relationship Proposed wording 
1685 Naturligt astaxanthin från 
den encelliga grönalgen 
Haematococcus pluvialis. 
Clarification provided 
Natural astaxanthin from 
unicellular alga 
Haematococcus pluvialis. 
Musklernas funktion. 
Clarification provided 
Muscle function. 
Astaxanthin ger musklerna god 
uthållighet och alert kropp vid 
träning.#C 
Astaxanthin maintains good muscle 
persistence and alert body at 
exercise.#C 
Clarification provided 
Astaxanthin maintains good muscle 
persistence and alert body at 
exercise.#C 
Conditions of use 
- Daglig dos 4-8 mg astaxanthin. Personer som tränar hårt bör ta 8 mg astaxanthin per dag. 
Effekt uppnås efter regelbunden användning i 4 – 24 veckor. 
Comments from Member States 
For items 1685-1689, all astaxanthin, EFSA comment is 6, which means only translation. SE is 
waiting for a validation and probably a new clarification. 
ID Food or Food constituent Health Relationship Proposed wording 
1686 Naturligt astaxanthin från 
den encelliga grönalgen 
Haematococcus pluvialis. 
Clarification provided 
Natural astaxanthin from 
unicellular alga 
Haematococcus pluvialis. 
Inverkan på mag- och 
tarmhälsa. 
Clarification provided 
Gut health: Influence on 
Helicobacter pylori 
infection. 
Astaxanthin främjar en god 
magfunktion.#C 
Astaxanthin improves stomach 
comfort.#C 
Clarification provided 
Astaxanthin improves stomach 
comfort.#C 
Conditions of use 
- Daglig dos 4-40 mg astaxanthin per dag. Dosering om mer än 20 mg astaxanthin per dag 
under högst 4 veckor i följd. Effekt uppnås vid regelbunden användning efter 1-2 veckor. 
Comments from Member States 
For items 1685-1689, all astaxanthin, EFSA comment is 6, which means only translation. SE is 
waiting for a validation and probably a new clarification. 
ID Food or Food constituent Health Relationship Proposed wording 
1687 Naturligt astaxanthin från 
den encelliga grönalgen 
Haematococcus pluvialis. 
Clarification provided 
Natural astaxanthin from 
unicellular alga 
Inverkan på hudens 
egenskaper. 
Clarification provided 
Skin health. 
Astaxanthin är bra för hudens 
fuktighet och elasticitet samt skyddar 
mot UV-strålning.#A 
Astaxanthin promotes skin moisture 
and elasticity plus protect against 
UV-irradiation.#A 
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Haematococcus pluvialis. Clarification provided 
Astaxanthin promotes skin moisture 
and elasticity plus protect against 
UV-irradiation.#A see MS comment 
Conditions of use 
- Daglig dos 2-4 mg astaxanthin. Effekt uppnås efter regelbunden användning i 2-4 veckor. 
Comments from Member States 
For items 1685-1689, all astaxanthin, EFSA comment is 6, which means only translation. SE is 
waiting for a validation and probably a new clarification. 
ID Food or Food constituent Health Relationship Proposed wording 
1688 Naturligt astaxanthin från 
den encelliga grönalgen 
Haematococcus pluvialis. 
Clarification provided 
Natural astaxanthin from 
unicellular alga 
Haematococcus pluvialis. 
Spermiernas funktion. 
Clarification provided 
Sperms motility. 
Astaxanthin främjar 
spermierna/sädescellernas rörlighet 
och funktion.#C 
Astaxanthin promotes sperms motility 
and functionality.#C 
Clarification provided 
Astaxanthin promotes sperms motility 
and functionality.#C see MS 
comment. 
Conditions of use 
- Daglig dos 16 mg astaxanthin. Effekt uppnås efter regelbunden användning i 3 månader. 
Comments from Member States 
For items 1685-1689, all astaxanthin, EFSA comment is 6, which means only translation. SE is 
waiting for a validation and probably a new clarification. 
ID Food or Food constituent Health Relationship Proposed wording 
1689 Naturligt astaxanthin från 
den encelliga grönalgen 
Haematococcus pluvialis. 
Clarification provided 
Natural astaxanthin from 
unicellular alga 
Haematococcus pluvialis. 
Immunsystemet. 
Clarification provided 
Immune system. 
Astaxanthin är en biologiskt aktiv 
antioxidant som skyddar kroppens 
celler och bidrar till att främja 
immunsystemets funktion. 
Astaxanthin is strong antioxidant 
protecting the cells in the body and it 
helps to maintain the immune system. 
Clarification provided 
Astaxanthin is strong antioxidant 
protecting the cells in the body and it 
helps to maintain the immune system. 
Conditions of use 
- Daglig dos 2-16 mg astaxanthin. Effekt uppnås efter regelbunden användning 2-16 veckor. 
Comments from Member States 
For items 1685-1689, all astaxanthin, EFSA comment is 6, which means only translation. SE is 
waiting for a validation and probably a new clarification. 
Astaxanthin related health claims 
 
18 EFSA Journal 2011;9(6):2206 
ID Food or Food constituent Health Relationship Proposed wording 
1919 Astaxanthin from 
Haematococcus pluvialis 
Supports Healthy 
Immune System 
Clarification provided 
Supports Healthy 
Immune System by 
modulation of 
biochemicals that cause 
inflammation 
Supports anti-aging through cellular 
health. Supports a healthy response to 
physiologic al stress. Supports 
healthy immune function. Protects 
DNA. 
Conditions of use 
- 4 – 12 mg dose daily. 
ID Food or Food constituent Health Relationship Proposed wording 
1979 Astaxanthin from 
Haematococcus pluvialis. 
Protects skin from UV 
damage and sun 
exposure. 
Supports skin structure during sun 
exposure.  
Supports healthy skin. 
Conditions of use 
- Minimum dose of 4 mg astaxanthin daily. 
- 3.85 mg astaxanthin (low dose) -19.25 mg astaxanthin (high dose) for 8 weeks. No negative 
effects on health have been described for 8 weeks. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1980 Astaxanthin from 
Haematococcus pluvialis. 
Supports Healthy 
Immune System. 
Supports anti-aging through cellular 
health. Supports a healthy response to 
physiological stress. Supports healthy 
immune function. Protects DNA. 
Conditions of use 
- 4 – 12 mg dose daily. 
No clarification provided by Member States 
 
 
